1341. [Definitions of oligometastatic disease and new treatment concepts].
The definition of oligometastatic disease has evolved into distinct intermediate stages of different prognosis between single metastasis and polymetastatic disease. We assessed the therapeutic impact of such clinical definitions based on a review of the literature. Increasingly advanced stages of the metastatic disease with some prominent oligometastatic targets can be treated with stereotactic irradiation with ablative intent owing to its excellent tolerance profile. Used in different settings, metastatic ablation can either prolong progression free survival, delay change of systemic therapy or delay the time to symptoms. It may also improve survival, quality of life and health care costs in some situations. While most approaches have studied metastases by anatomic site rather than histology, combined systemic-ablative local treatment approaches are being developed for cancers of similar behavior. Biology-driven and imaging-oriented approaches are being investigated to better identify metastatic profiles for treatment guidance.
1354. [The liquid biopsies: What is their contribution to the management of cancer?].
The « liquid biopsies » are samples of liquids such as blood, urine, spinal fluid that can contain tumor material. Clinical assays have been mainly focused on the peripheral blood containing circulating tumor cells and circulating tumor DNA. The circulating tumor cells are cancer cells released from the primary tumor or recurrences or metastases. They enter into the bloodstream after passing through the vessel wall. It is possible to analyze the circulating tumor cells by means of all cytologic and biomolecular techniques. The free circulating tumor DNA is made of fragments of DNA released by living or necrotic tumor cells proceeded from any place of the organism. The free circulating tumor DNA and DNA from circulating tumor cells show structural rearrangements among which some are therapeutic targets. Many studies showed that circulating tumor cells and circulating tumor DNA analyses are useful in revealing recurrences and tracking therapeutic targets.
1356. [Where do we stand with benign prostatic hyperplasia day-case surgery: A laser effect?].
Despite its feasibility has been proven, Benign Prostatic Hyperplasia (BPH) day-case surgery remains uncommon. Our objective was to describe the evolution of BPH day-case surgery in France according to the surgical technique employed.
1357. [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?].
作者: M E Meunier.;Y Neuzillet.;C Radulescu.;C Cherbonnier.;J-M Hervé.;M Rouanne.;V Molinié.;T Lebret.
来源: Prog Urol. 2018年28卷10期475-481页
The influence of the delay between prostate biopsy and radical prostatectomy for patients with localized prostate cancer is controversial. The objective of this study was to establish a time limit between prostate biopsy and radical prostatectomy beyond which the risks of upgradging and biochemical recurrence (BCR) are increased.
1359. [Cutaneous melanoma: from rationalized models to patients care].
Cutaneous melanoma derives from the tumoral transformation of melanocytes. These pigmented cells produce melanin prior transmitting it to the surrounding keratinocytes of the skin, hair and mane. The main function of melanin is to protect cells and their DNA from damage caused by ultraviolet light. Melanoma is the most aggressive skin cancer whose incidence has increased steadily in recent decades. Advances in basic research have resulted in a better understanding of the molecular and cellular events responsible for the initiation and progression of melanomas. In this review, we present an overview of the knowledge gained in recent years and show how recent advances lead to new targeted and more efficient therapeutic approaches.
|